Facebook
Twitter
Telegram
Report an ErrorUltragenyx Pharmaceutical Cash Flow 2011-2024 | RARE
Annual Cash Flow Ultragenyx Pharmaceutical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-475 M | -380 M | -339 M | -132 M | -345 M | -291 M | -254 M | -161 M | - | - | - | - | - |
Depreciation & Amortization |
26 M | 18.2 M | 13.2 M | 12.3 M | 8.54 M | 19.5 M | 5.82 M | 3.42 M | 1.38 M | 684 K | 444 K | 313 K | - |
Accounts Payables |
42.1 M | 43.3 M | 17.1 M | 12.9 M | 12.9 M | 12.3 M | 8.89 M | 5.36 M | 2.94 M | 4.86 M | - | - | - |
Accounts Receivables |
73.4 M | 40.4 M | 28.4 M | 23.1 M | 32.8 M | 12.7 M | 5.17 M | - | - | - | - | - | - |
Total Inventories |
34 M | 26.8 M | 16.2 M | 13 M | 11.5 M | 7.06 M | 757 K | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Ultragenyx Pharmaceutical
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-191 M | - | - | - | -157 M | - | - | - | -118 M | - | - | - | -159 M | - | -69.8 M | -7.8 M | -95.2 M | - | -273 M | -185 M | -95.8 M | - | -235 M | -166 M | -89.5 M | - | -172 M | -110 M | - | - | - | - | - | - | - | - | - | - | - | - | -8.34 M | - | -21.4 M | -14.7 M | -6.29 M | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
8.84 M | - | - | - | 5.24 M | - | - | - | 4.09 M | - | - | - | 3.37 M | - | 9.13 M | 6.04 M | 2.85 M | - | 6.37 M | 4.22 M | 2.12 M | - | 16.6 M | 12.2 M | 6.16 M | - | 3.31 M | 2.22 M | 1.16 M | - | 2.27 M | 1.24 M | 544 K | - | 904 K | 463 K | 201 K | - | 472 K | 278 K | 117 K | - | 332 K | 227 K | 124 K | - | - | - | - | - | - | - | - |
Accounts Payables |
41 M | 42.1 M | 33.4 M | 42.1 M | 59 M | 43.3 M | 23.5 M | 34.2 M | 23.7 M | 17.1 M | 15.6 M | 21.8 M | 15.7 M | 12.9 M | 10.8 M | 9.01 M | 14.4 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 8.89 M | 8.89 M | 8.89 M | 8.89 M | 5.36 M | 5.36 M | 5.36 M | 5.36 M | 2.94 M | 2.94 M | 2.94 M | 2.94 M | 4.86 M | 4.86 M | 4.86 M | 4.86 M | 1.44 M | 1.44 M | 1.44 M | 1.44 M | - | - | - | - | - | - | - | - |
Accounts Receivables |
- | - | - | - | - | - | - | - | 28.4 M | 28.4 M | 25.4 M | 24.7 M | 25 M | 23.1 M | 23.1 M | 23.1 M | 23.1 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 5.17 M | 5.17 M | 5.17 M | 5.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
35.9 M | 34 M | 31.8 M | 28.3 M | 26.6 M | 26.8 M | 21.8 M | 21.1 M | 17.8 M | 16.2 M | 15.2 M | 15.1 M | 12.5 M | 13 M | 14.5 M | 11.1 M | 11.4 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 7.06 M | 7.06 M | 7.06 M | 7.06 M | 757 K | 757 K | 757 K | 757 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency